Proactive Investors - Run By Investors For Investors

The Hydroponics Company supplies first Australian patients prescribed cannabidiol products

The company is building a strong supply chain in anticipation of the launch of its proprietary manufactured products in 2019.
The Hydroponics Company supplies first Australian patients prescribed cannabidiol products
The medical cannabis company is vertically integrated from 'Farm-to-Pharma'

The Hydroponics Company Ltd (ASX:THC) has supplied Endoca cannabidiol (CBD) products to its first prescribed Australian patients.

The supply has verified THC’s product pathway from manufacturer through to patient under federal authorised prescriber and special access schemes, as well as relevant state regulations.

THC is currently importing four products from Endoca’s range: Endoca’s CBD oil in 3% and 15% concentrations; and Endoca’s unique CBD-plus-CBDa oils also in 3% and 15% concentrations.

THC is also preparing to change its company name to THC Global Group Limited, with a resolution to be put forward at the company’s annual general meeting on November 15.

READ: The Hydroponics Company well placed to grow as Canada set to legalise recreational cannabis

THC chief executive officer Ken Charteris said: “The ability to secure supply of high-quality GMP-certified medicinal cannabis products to domestic patients is a key bridge to implementation of THC Global’s ‘Farm-to-Pharma’ model.

“We continue to build out our domestic infrastructure in Australia under our Farm-to-Pharma model – research, growing, manufacture and supply.”

 

READ: The Hydroponics Company to change name to THC Global Group Limited

THC is building patient and prescriber awareness including sponsoring educational events to highlight the benefits of treatment with medicinal cannabis and the pathways to access the product in Australia.

As awareness increases within the domestic market, THC expects to see corresponding increases in revenue-generating product sales.

The company has also made available documentation for doctors and other prescribers to assist in prescribing Endoca’s products in Australia under the authorised prescriber and special access schemes.

View full THC profile View Profile

THC Global Group Ltd Timeline

Related Articles

test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
lab worker
May 20 2019
Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology
1550850611_CancerHeadline.jpg
February 23 2019
Broker Hybridan reckons Sareum is “arguably a bargain target for the relatively large group of biotech and pharma companies interested in TYK2 and the wider JAK inhibitor space”

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use